Skip to content

20-198 - Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis

Status: open

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety

Patients with Relapsing Multiple Sclerosis

Contact Us Or call +1 (251) 665-8375


Phase 3 clinical trial testing the safety and efficacy of a new drug for multiple sclerosis called evobrutinib


This trial is sponsored by Merck.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.